Chimerix 대차 대조표 상태

재무 상태 기준 확인 6/6

Chimerix 의 총 주주 지분은 $135.8M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $158.7M 및 $22.9M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$136.23m
주식	US$135.78m
총 부채	US$22.89m
총 자산	US$158.67m

최근 재무 상태 업데이트

Recent updates

재무 상태 분석

단기부채: CXF 의 단기 자산 ( $140.9M )이 단기 부채( $22.2M ).

장기 부채: CXF 의 단기 자산( $140.9M )이 장기 부채( $644.0K ).

부채 대 자본 내역 및 분석

부채 수준: CXF 부채가 없습니다.

부채 감소: CXF 5년 전에 부채가 없었습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: CXF 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: CXF 2.3 1.5 2.3 % 매년.

Chimerix 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Recent updates

Third quarter 2024 earnings released: US$0.26 loss per share (vs US$0.27 loss in 3Q 2023)

Chimerix, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.21 loss in 2Q 2023)

Chimerix, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.24 loss in 1Q 2023)

Chimerix, Inc., Annual General Meeting, Jun 20, 2024

Chimerix, Inc. to Report Q1, 2024 Results on May 01, 2024

Chimerix Appoints Marc D. Kozin to Board of Directors

Full year 2023 earnings released: US$0.93 loss per share (vs US$1.97 profit in FY 2022)

Chimerix, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Chimerix Announces Board Changes

Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer

Chimerix, Inc. Appoints Michelle Laspaluto to Chief Financial Officer

Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer

Third quarter 2023 earnings released: US$0.27 loss per share (vs US$2.75 profit in 3Q 2022)

Chimerix, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.27 loss in 2Q 2022)

Chimerix, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023

Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Growth Index

CEO, President & Director recently bought €90k worth of stock

First quarter 2023 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2022)

Full year 2022 earnings released: EPS: US$1.97 (vs US$2.04 loss in FY 2021)

Insufficient new directors

Chimerix, Inc. Announces Successful Launch of ONC201 Phase 3 Action Study

Rubric Capital Management Sends Letter to Chimerix

Third quarter 2022 earnings released: EPS: US$2.75 (vs US$0.21 loss in 3Q 2021)

Emergent BioSolutions Inc. (NYSE:EBS) completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $370 million.

Forecast to breakeven in 2022

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.21 loss in 2Q 2021)

Chimerix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

First quarter 2022 earnings released: US$0.28 loss per share (vs US$1.22 loss in 1Q 2021)

Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million.

Chimerix, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Chimerix, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative Announces Late-Breaking Oral Presentation At International Conference on Antiviral Research

Chimerix, Inc. Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in 3Q 2020)

Forecast to breakeven in 2023

Independent Director recently bought €65k worth of stock

Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

Forecast to breakeven in 2024

First quarter 2021 earnings released: US$1.22 loss per share (vs US$0.17 loss in 1Q 2020)

Full year 2020 earnings released: US$0.70 loss per share (vs US$2.03 loss in FY 2019)

Revenue misses expectations

Chimerix, Inc. Reports Topline Results from the First Cohort of Its Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study

New 90-day high: €8.81

New 90-day high: €7.91

Chimerix, Inc. (NasdaqGM:CMRX) acquired Oncoceutics, Inc. from Spring Mountain Capital, LP and others for $68.3 million

New 90-day high: €6.58

New 90-day high: €3.46

New 90-day high: €2.58

Revenue beats expectations

Third quarter 2020 earnings released: US$0.18 loss per share

Chimerix, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €1.93

New 90-day low - €2.22

New 90-day low - €2.47

First half earnings released

Chimerix, Inc. to Report Q2, 2020 Results on Aug 10, 2020

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석